Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68,540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X. Wang H, et al. Among authors: yang x. Cell. 2020 Aug 6;182(3):713-721.e9. doi: 10.1016/j.cell.2020.06.008. Epub 2020 Jun 6. Cell. 2020. PMID: 32778225 Free PMC article.
Cryo-EM structure of the varicella-zoster virus A-capsid.
Sun J, Liu C, Peng R, Zhang FK, Tong Z, Liu S, Shi Y, Zhao Z, Zeng WB, Gao GF, Shen HJ, Yang X, Luo M, Qi J, Wang P. Sun J, et al. Among authors: yang x. Nat Commun. 2020 Sep 22;11(1):4795. doi: 10.1038/s41467-020-18537-y. Nat Commun. 2020. PMID: 32963252 Free PMC article.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Xia S, et al. Among authors: yang x, yang y. Lancet Infect Dis. 2021 Jan;21(1):39-51. doi: 10.1016/S1473-3099(20)30831-8. Epub 2020 Oct 15. Lancet Infect Dis. 2021. PMID: 33069281 Free PMC article. Clinical Trial.
Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
Zhou X, Wang H, Ji Q, Du M, Liang Y, Li H, Li F, Shang H, Zhu X, Wang W, Jiang L, Stepanov AV, Ma T, Gong N, Jia X, Gabibov AG, Lou Z, Lu Y, Guo Y, Zhang H, Yang X. Zhou X, et al. Among authors: yang x. Protein Cell. 2021 Oct;12(10):818-823. doi: 10.1007/s13238-021-00840-z. Epub 2021 Apr 28. Protein Cell. 2021. PMID: 33909239 Free PMC article. No abstract available.
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Al Kaabi N, et al. Among authors: yang t, yang x, yang y. JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565. JAMA. 2021. PMID: 34037666 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang W, Zhang W, Li N, Xie Z, Zhu X, Ding L, You W, Zhao Y, Zhao J, Huang L, Shi X, Yang Y, Xu G, Wang W, Liu P, Ma M, Qiao Y, Zhao S, Chai J, Li Q, Fu H, Xu Y, Zheng X, Guo W, Yang X. Xia S, et al. Among authors: yang x, yang y. Lancet Infect Dis. 2022 Feb;22(2):196-208. doi: 10.1016/S1473-3099(21)00462-X. Epub 2021 Sep 15. Lancet Infect Dis. 2022. PMID: 34536349 Free PMC article. Clinical Trial.
Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma.
Yu D, Li YF, Liang H, Wu JZ, Hu Y, Peng Y, Li TJ, Hou JF, Huang WJ, Guan LD, Han R, Xing YT, Zhang Y, Liu J, Feng L, Li CY, Liang XL, Ding YL, Zhou ZJ, Ji DM, Wang FF, Yu JH, Deng K, Xia DM, Dong DM, Hu HR, Liu YJ, Fu DX, He YL, Zhou DB, Yang HC, Jia R, Ke CW, Du T, Xie Y, Zhou R, Li CS, Wang ML, Yang XM. Yu D, et al. Adv Sci (Weinh). 2022 May;9(14):e2104333. doi: 10.1002/advs.202104333. Epub 2022 Apr 11. Adv Sci (Weinh). 2022. PMID: 35403837 Free PMC article.
Nasal delivery of broadly neutralizing antibodies protects mice from lethal challenge with SARS-CoV-2 delta and omicron variants.
Lu J, Yin Q, Pei R, Zhang Q, Qu Y, Pan Y, Sun L, Gao D, Liang C, Yang J, Wu W, Li J, Cui Z, Wang Z, Li X, Li D, Wang S, Duan K, Guan W, Liang M, Yang X. Lu J, et al. Among authors: yang x, yang j. Virol Sin. 2022 Apr;37(2):238-247. doi: 10.1016/j.virs.2022.02.005. Epub 2022 Feb 18. Virol Sin. 2022. PMID: 35527227 Free PMC article.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: yang t, yang xm, yang yk, yang ss, yang m. Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2. Signal Transduct Target Ther. 2022. PMID: 35665745 Free PMC article. Clinical Trial.
68,540 results
You have reached the last available page of results. Please see the User Guide for more information.